BBIO · BridgeBio Pharma, Inc. · Executive Compensation
$76.03
-2.15 (-2.75%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$14.81B
Shares
194.80M
Volume · Nov 20
1.48M
Avg daily vol (3M)
2.65M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $14,944,585 |
| Thomas Trimarchi | President and Chief Financial Officer | $5,832,369 |
| Brian Stephenson | Ph.D., CFA Former Chief Financial Officer | $684,661 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $15,581,923 |
| Thomas Trimarchi | President and Chief Financial Officer | $6,502,058 |
| Brian Stephenson | Ph.D., CFA Former Chief Financial Officer | $5,663,687 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $12,158,626 |
| Brian Stephenson | Ph.D., CFA Former Chief Financial Officer | $6,651,996 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $6,674,437 |
| Brian Stephenson | Ph.D., CFA Former Chief Financial Officer | $2,957,392 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $25,626,959 |
| Brian Stephenson | Ph.D., CFA Chief Financial Officer | $8,677,297 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $10,054,909 |
| Michael Henderson | Chief Business Officer | $7,991,241 |
| Brian Stolz | Chief Operating Officer | $5,240,851 |
| Cameron Turtle | Ph.D.\ Chief Strategy Officer | $4,561,482 |
| Brian Stephenson | Ph.D., CFA Chief Financial Officer | $4,163,933 |
| Charles Homcy | Chairman of Pharmaceuticals | $1,855,805 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Neil Kumar | Chief Executive Officer | $26,334,063 |
| Brian Stolz | Chief Operating Officer | $8,146,313 |
| Charles Homcy | Chairman of Pharmaceuticals | $5,975,842 |
| Brian Stephenson | Ph.D., CFA Chief Financial Officer | $4,198,967 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Brian Stephenson | Ph.D., CFA Chief Financial Officer | $2,347,115 |
| Neil Kumar | Chief Executive Officer | $450,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Hannah A. Valantine, M.D. | Class I director | Appointed | 2026-06-26 |
| Frank P. McCormick, Ph.D. | Class I director | Appointed | 2026-06-26 |
| James C. Momtazee | Class I director | Appointed | 2026-06-26 |
|
Randal W. Scott
“Dr. Scott’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2026-06-26 |
| Thomas Trimarchi | President and Chief Financial Officer (CFO) | Appointed | 2025-03-17 |
|
Brian C. Stephenson
“Dr. Stephenson's departure was not the result of a disagreement with the Company on any matters relating to the Company’s operations, policies or practices.”
|
Chief Financial Officer | Terminated | 2025-03-17 |
| Thomas Trimarchi | President and Chief Operating Officer | Appointed | 2024-07-23 |
| Frank McCormick | director | Appointed | 2023-02-23 |
|
Brenton L. Saunders
“Dr. Scheller’s and Mr. Saunders’ resignations were not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2023-02-23 |
|
Richard H. Scheller
“Dr. Scheller’s and Mr. Saunders’ resignations were not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2023-02-23 |
| Hannah A. Valantine | Class I director | Appointed | 2021-10-26 |
| Douglas Dachille | director | Appointed | 2021-08-23 |
| Andrea Ellis | director | Appointed | 2021-08-23 |
| Fred Hassan | director | Appointed | 2021-08-23 |
Leadership
- Neil Kumar CEO, Board Member
- Charles Homcy Chairman, Board Member
- Brian Stephenson CFO
- Thomas Trimarchi CFO, COO
- Brian Stolz COO
- Brian C. Stephenson Chief Accounting Officer
- Ali J. Satvat Board Member
- Andrea Ellis Board Member
- Andrea J. Ellis Board Member
- Andrew W. Lo Board Member
- Douglas A. Dachille Board Member
- Douglas Dachille Board Member
- Dr. Hannah A. Valantine Board Member
- Eric Aguiar Board Member
- Frank McCormick Board Member
- Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) Board Member
- Frank P. McCormick Board Member
- Frank P. McCormick, Ph.D. Board Member
- Fred Hassan Board Member
- Hannah A. Valantine Board Member
- Hannah A. Valantine, M.D. Board Member
- James C. Momtazee Board Member
- Jennifer E. Cook Board Member
- Ronald J. Daniels Board Member
Key facts
CIK
1743881
CUSIP
10806X102
13F (30d)
465 filings
434 filers
Visit website
Investor relations